{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:41:53Z","timestamp":1787316113932,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1124\/jpet.111.182063","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T21:46:50Z","timestamp":1305064010000},"page":"622-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist"],"prefix":"10.1016","volume":"338","author":[{"given":"Marla L.","family":"Watt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hitchcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Chesterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McKinzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian C.","family":"Felder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.182063_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.111.182063_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/mol.110.064345","article-title":"Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor","volume":"78","author":"Avlani","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.182063_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.111.182063_bib4","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1523\/JNEUROSCI.08-12-04646.1988","article-title":"Localization of a family of muscarinic receptor mRNAs in rat brain","volume":"8","author":"Buckley","year":"1988","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.182063_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0006-8993(98)00267-4","article-title":"Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects","volume":"795","author":"Bymaster","year":"1998","journal-title":"Brain Res"},{"key":"10.1124\/jpet.111.182063_bib6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1460-9568.2003.02588.x","article-title":"Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity","volume":"17","author":"Bymaster","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.111.182063_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","article-title":"International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.111.182063_bib8","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1073\/pnas.0800567105","article-title":"Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia","volume":"105","author":"Chan","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.111.182063_bib9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.111.182063_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.111.182063_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","article-title":"Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.111.182063_bib12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"7","author":"Dean","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.111.182063_bib13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0022-3565(24)38222-9","article-title":"Determination of [35S]guanosine-5\u2032-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay","volume":"289","author":"DeLapp","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.182063_bib14","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0024-3205(01)01059-1","article-title":"Elucidating the role of muscarinic receptors in psychosis","volume":"68","author":"Felder","year":"2001","journal-title":"Life Sci"},{"key":"10.1124\/jpet.111.182063_bib15","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1074\/jbc.M109.094011","article-title":"Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias","volume":"285","author":"Gregory","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.182063_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.lfs.2003.07.005","article-title":"The [35S]GTP-gamma-S binding assay: approaches and applications in pharmacology","volume":"74","author":"Harrison","year":"2003","journal-title":"Life Sci"},{"key":"10.1124\/jpet.111.182063_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","article-title":"Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists","volume":"605","author":"Heinrich","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.182063_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev.pa.30.040190.003221","article-title":"Muscarinic receptor subtypes","volume":"30","author":"Hulme","year":"1990","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.111.182063_bib19","first-page":"S117","article-title":"TBPB is a highly selective M1 allosteric muscarinic receptor agonist in vitro and produces robust antipsychotic-like effects in vivo","volume":"31","author":"Jones","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.111.182063_bib20","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1523\/JNEUROSCI.1850-08.2008","article-title":"Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats","volume":"28","author":"Jones","year":"2008","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.182063_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pharmthera.2004.05.002","article-title":"Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function","volume":"103","author":"Kristiansen","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.111.182063_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.111.182063_bib23","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1073\/pnas.93.24.13541","article-title":"Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease","volume":"93","author":"Levey","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.111.182063_bib24","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.111.182063_bib25","first-page":"740","article-title":"Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials","volume":"11","author":"McArthur","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.111.182063_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molbrainres.2004.09.012","article-title":"Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice","volume":"133","author":"Oki","year":"2005","journal-title":"Mol Brain Res"},{"key":"10.1124\/jpet.111.182063_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jchemneu.2010.03.005","article-title":"Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer\u2019s disease","volume":"40","author":"Overk","year":"2010","journal-title":"J Chem Neuroanat"},{"key":"10.1124\/jpet.111.182063_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(02)02721-X","article-title":"M1 muscarinic receptor signaling in mouse hippocampus and cortex","volume":"944","author":"Porter","year":"2002","journal-title":"Brain Res"},{"key":"10.1124\/jpet.111.182063_bib29","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1073\/pnas.0914801107","article-title":"The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation\/arrestin-dependent manner","volume":"107","author":"Poulin","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.111.182063_bib30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia","volume":"12","author":"Raedler","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.111.182063_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13651509809115353","article-title":"Twenty years of cholinergic intervention in Alzheimer\u2019s disease: a tale of disappointment and ultimate confidence","volume":"2","author":"Rainer","year":"1998","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1124\/jpet.111.182063_bib32","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.111.182063_bib33","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.182063_bib34","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0026-895X(24)12088-3","article-title":"Discovery of an ectopic activation site on the M1 muscarinic receptor","volume":"61","author":"Spalding","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.182063_bib35","series-title":"Essential Psychopharmacology","author":"Stahl","year":"2000"},{"key":"10.1124\/jpet.111.182063_bib36","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/jpet.109.160242","article-title":"Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation","volume":"331","author":"Thomas","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.182063_bib37","doi-asserted-by":"crossref","first-page":"29312","DOI":"10.1074\/jbc.M803801200","article-title":"A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric\/allosteric ligand","volume":"283","author":"Valant","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.111.182063_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/mi.9.3.6","article-title":"Orthosteric\/allosteric bitopic ligands: going hybrid at GPCRs","volume":"9","author":"Valant","year":"2009","journal-title":"Mol Interv"},{"key":"10.1124\/jpet.111.182063_bib39","first-page":"531","article-title":"Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia","volume":"8","author":"Vohora","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.111.182063_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1615\/CritRevNeurobiol.v10.i1.40","article-title":"Molecular biology of muscarinic acetylcholine receptors","volume":"10","author":"Wess","year":"1996","journal-title":"Crit Rev Neurobiol"},{"key":"10.1124\/jpet.111.182063_bib41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","article-title":"Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development","volume":"6","author":"Wess","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.182063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:33:42Z","timestamp":1740000822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524464951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0022356524464951"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.182063","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.182063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}